Older Psoriasis Patients Face Access and Dosing Hurdles

Older adults with psoriasis are running into a familiar wall: getting the therapy is only half the battle — sticking to it is the other. Dermatology Times' latest clinical feature, "Access, Adherence, and Dosing Frequency in Older Psoriasis Patients," takes aim at that gap.

The piece centers on a population clinicians see daily but study rarely. Patients over 65 with psoriasis sit at the intersection of polypharmacy, fixed incomes, and treatment regimens that weren't designed for them. And dosing frequency, the analysis argues, may matter more in this cohort than in any other.

Why dosing frequency is the sticking point

The core tension the article lays out is straightforward. A therapy that works on paper can fail in practice if the schedule fights the patient's life. For older adults managing multiple chronic conditions, each additional administration step is another chance for a missed dose.

That's not a marginal concern. Adherence failures in chronic dermatologic disease routinely undermine clinical outcomes that looked solid in registration trials — trial populations skew younger and healthier than the average waiting room.

Access compounds it. Insurance hurdles, prior authorization delays, and cost-sharing structures hit fixed-income patients hardest, and dermatologists know the downstream cost: a gap in therapy often reads, clinically, as a failure of therapy.

What does this change for the clinician?

The practical question for prescribers is which levers actually move adherence in this group. The Dermatology Times feature points toward regimen simplicity — less frequent dosing, clearer administration pathways — as the variable clinicians can control at the point of prescribing.

For a field that has spent the last decade accumulating biologics with increasingly favorable dosing intervals, the piece is a reminder that the pharmacology only delivers if the logistics hold. Matching agent selection to a specific patient's capacity to comply isn't bedside manner; it's outcome management.

The feature also implicitly raises a research gap. Real-world adherence data specific to older psoriasis patients remain thin relative to the size of the aging population dermatology is now serving — a cohort growing every year as demographics shift.

Watch for regimen design and access policy to keep colliding in this space as the over-65 psoriasis population expands.